

Provided by:



GI Oncology Multidisciplinary Case Conference and Tumor Board 2025-2026

GI Oncology Multidisciplinary Case Conference and Tumor Board 2025-2026 - 12/31/2025

December 31, 2025

1:30 PM - 2:30 PM

PCAM South Tower 12th Floor Conference Room 12-122 and/or via MS Teams

Target Audience

This program has been designed for DIAGNOSTIC RADIOLOGY, CLINICAL GENETICS AND GENOMICS (MD), INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, INTERNAL MEDICINE - Gastroenterology, INTERNAL MEDICINE, DIAGNOSTIC MEDICAL PHYSICS, COLON AND RECTAL SURGERY, PATHOLOGY - ANATOMIC, MEDICAL GENETICS AND GENOMICS - Medical Biochemical Genetics, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss and collaborate on the patient's treatment plan in an interprofessional and interdisciplinary setting.
- 2 Describe state-of-the-art diagnostic and treatment methods for the conditions presented, incorporating the latest evidence-based practices.
- 3 Describe and apply the standard of care for patient management, as outlined in national practice guidelines.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
Roberto Lorenzo, Franklin Ingram
(215) 349-5955, (267) 240-0583

roberto.lorenzo@uphs.upenn.edu, frank.ingram@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Parul Agarwal, MD	Other Planning Committee Member	Nothing to disclose - 05/07/2025
Edgar Ben-Josef, MD	Course Director	Nothing to disclose - 06/03/2025
Emma Briscoe, MSN	Other Planning Committee Member	Nothing to disclose - 12/05/2025
William Chapin, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Replimune Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merus Grant or research support-Merus Grant or research support-Genentech Grant or research support-Replimune Grant or research support-Boehringer-Ingelheim Other: Travel Support - Dava Oncology (Relationship has ended) - 05/22/2025
Et-Tsu Chen, MD	Other Planning Committee Member	Nothing to disclose - 04/22/2025
Robin Collingwood, MD	Other Planning Committee Member	Nothing to disclose - 07/21/2025
Nevena Damjanov, MD	Other Planning Committee Member	Nothing to disclose - 07/13/2025
Erin Davis, CRNP	Nurse Planner	Nothing to disclose - 08/18/2025
Ronald P DeMatteo, MD	Other Planning Committee Member	Nothing to disclose - 07/10/2025

Tracy d'Entremont, MD	Other Planning Committee Member	Nothing to disclose - 07/30/2025
Ali Dhanaliwala, MD, PhD	Other Planning Committee Member	Nothing to disclose - 07/14/2025
Efrat Dotan, MD	Other Planning Committee Member	Advisor-Ipsen (Relationship has ended) Grant or research support-Relay (Relationship has ended) Consulting Fee-Lutris Pharmaceuticals (Relationship has ended) Grant or research support-Lutris (Relationship has ended) Consulting Fee-Jazz Pharmaceuticals Advisor-AbbVie, Inc. (Relationship has ended) Advisor-TME Therapeutics (Relationship has ended) Advisor-Merus (Relationship has ended) Advisor-Amgen (Relationship has ended) Advisor-Agenus (Relationship has ended) Advisor-Merck & Co (Relationship has ended) Grant or research support-Ipsen - 11/28/2025
Amr K El Jack, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Danielle Fortuna, MD	Other Planning Committee Member	Nothing to disclose - 12/10/2025
Adam F\ Fredo, PA-C	Physician Assistant Planner	Nothing to disclose - 12/04/2025
Emma Furth, MD	Other Planning Committee Member	Nothing to disclose - 07/14/2025
Patricia Gambino, MSN	Other Planning Committee Member	Nothing to disclose - 07/17/2025
Joanie Garratt, MD	Other Planning Committee Member	Nothing to disclose - 06/28/2025
Kathryn Green, CRNP	Other Planning Committee Member	Speakers Bureau-Aadi bio (Relationship has ended) Speakers Bureau-Astra Zeneca Pharmaceuticals - 07/11/2025
Lisa P Jones, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/28/2025
Karishma Khullar, MD	Other Planning Committee Member	Nothing to disclose - 07/07/2025
HyunTae Kim, MD	Other Planning Committee Member	Nothing to disclose - 07/23/2025
Pallavi Kumar, MD	Other Planning Committee Member	Nothing to disclose - 09/03/2025
Major K Lee IV, MD, PhD	Other Planning Committee Member	Nothing to disclose - 07/10/2025
Ryan Massa, MD	Other Planning Committee Member	Nothing to disclose - 11/24/2025
James Metz, MD	Other Planning Committee Member	Honoraria-Siemens Medical Solutions, Inc. Honoraria-Ion Beam Applications - 07/29/2025
Matthew Nazarian, MD	Other Planning Committee Member	Nothing to disclose - 05/07/2025
Mark O'Hara, MD	Other Planning Committee Member	Grant or research support-Bristol-Myers Squibb Grant or research support-Genmab Grant or research support-HiberCell

		(Relationship has ended) Grant or research support-Arcus Biosciences Grant or research support-Bellicum (Relationship has ended) Grant or research support-Natera (Relationship has ended) Grant or research support-Celldex (Relationship has ended) Grant or research support-Psioxus Consulting Fee-Geneos (Relationship has ended) Advisor-Alligator Bioscience (Relationship has ended) Grant or research support-Geistlich Grant or research support-Triumvera (Relationship has ended) Consulting Fee-Merus (Relationship has ended) Grant or research support-Elicio Grant or research support-Revolution Medicine Grant or research support-Verastem Grant or research support-Astra Zeneca Pharmaceuticals Grant or research support-Merck & Co - 07/10/2025
John Plastaras, MD	Other Planning Committee Member	Nothing to disclose - 06/30/2025
Elizabeth PrechtelDunphy, CRNP RN	Other Planning Committee Member	Honoraria-Incyte Corporation Honoraria-Astellas - 07/14/2025
Kim Reiss Binder, MD	Other Planning Committee Member	Advisor-Carisma Therapeutics (Relationship has ended) Advisor-Bristol-Myers Squibb Advisor-Foundation Medicine Advisor-Astra Zeneca Pharmaceuticals Grant or research support-Clovis Oncology (Relationship has ended) Grant or research support-Bristol-Myers Squibb Grant or research support-Glaxo Smith Kline - 03/07/2025
Shuchi K Rodgers, MD	Other Planning Committee Member	Royalties or Patent Beneficiary-Elsevier - 01/21/2025
Mark Rosen, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Hersh Sagreiya, MD, FCBC	Other Planning Committee Member	Nothing to disclose - 02/10/2025
Charles J Schneider, MD	Other Planning Committee Member	Nothing to disclose - 09/08/2025
Sherry Shang, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Evan S Siegelman, MD	Other Planning Committee Member	Paid consultant-Icon Medical Imaging Paid consultant-Bioclinica Inc Paid consultant-Invicro Inc (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Covera - 06/03/2025
Kristen Stashek, MD	Other Planning Committee Member	Nothing to disclose - 04/14/2025
Kalpana Suresh, MD	Other Planning Committee Member	Nothing to disclose - 07/23/2025
Ursina Teitelbaum, MD	Co-Director, Faculty	Nothing to disclose - 07/10/2025

Rashmi Tondon, MD	Other Planning Committee Member	Nothing to disclose - 12/04/2025
Charles M Vollmer Jr., MD	Other Planning Committee Member	Nothing to disclose - 07/14/2025
Debra Whorms, MD	Other Planning Committee Member	Nothing to disclose - 07/23/2025
Zhaohai Yang, MD	Other Planning Committee Member	Consulting Fee-Flagship Biosciences - 07/10/2025
Hanna Zafar, MD	Other Planning Committee Member	Nothing to disclose - 03/20/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected